The 340B Rebate Model Pilot takes effect January 1, 2026, covering 10 high-cost specialty medications from the Medicare Drug Price Negotiation list—drugs commonly accessed through referral capture programs. Once the rebate model goes into effect, securing 340B savings on these medications—discounts ranging from hundreds to thousands of dollars per prescription—will depend on meeting a strict 45-day submission deadline, placing new demands on pharmacy teams that are already stretched thin.
This session examines how the transition from upfront pricing to retrospective rebates impacts specialty referral workflows. The new model gives you 45 days from the date of dispensing to submit documentation proving 340B eligibility—creating narrow windows for tracking high-value prescriptions across multiple providers.
We'll cover the challenges of managing referral capture in a rebate-based system, the cash flow considerations for costly specialty drugs, and actionable approaches to sustain your specialty referral capture operations under the 340B rebate framework.